Global Transcatheter Heart Valve Replacement and Repair Market Size By Type (Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral Valve Repair (TMVR)), By Application (Hospitals, Ambula...

The Global Transcatheter Heart Valve Replacement and Repair Market was valued at USD 6.3 billion in 2023 and is projected to surpass USD 14.9 billion by 2031, growing at a CAGR of 11.4% during the forecast period from 2023 to 2031. This market is experiencing robust growth due to the rising prevalence of cardiovascular diseases, an aging population, and increasing adoption of minimally invasive procedures. Transcatheter techniques are becoming a preferred alternative to open-heart surgery, offering reduced recovery times and fewer complications, making them increasingly popular among patients and healthcare providers.

Drivers:

1. Increasing Prevalence of Cardiovascular Diseases:

Cardiovascular disorders, particularly valvular heart diseases such as aortic stenosis and mitral regurgitation, are becoming more common due to aging populations. This drives demand for advanced treatment options like transcatheter valve replacement and repair.

2. Technological Advancements in Transcatheter Devices:

Innovation in device design, including next-generation valves and delivery systems, is enhancing procedural success rates and expanding patient eligibility, which in turn accelerates market growth.

3. Growing Preference for Minimally Invasive Surgeries:

Minimally invasive transcatheter procedures offer shorter hospital stays, reduced risks, and faster recovery compared to traditional surgeries, making them the preferred choice among elderly and high-risk patients.

Restraints:

1. High Cost of Devices and Procedures:

The cost of transcatheter heart valve procedures remains high, limiting accessibility in cost-sensitive regions and placing a financial burden on healthcare systems.

2. Limited Skilled Professionals and Training:

Successful execution of transcatheter procedures requires specialized training and expertise, and the current shortage of trained professionals can restrict the adoption of these technologies, especially in developing countries.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Asia-Pacific and Latin America present significant opportunities due to improving healthcare infrastructure, growing awareness, and increasing investment in advanced cardiovascular care.

2. Clinical Trials and Approvals for Expanded Indications:

Ongoing clinical research is likely to result in broader indications for use, enabling treatment of wider patient populations and driving adoption of transcatheter solutions.

Market by System Type Insights:

The Transcatheter Aortic Valve Replacement (TAVR) segment accounted for the largest market share in 2023. TAVR is a widely adopted and clinically validated procedure for treating aortic valve stenosis, especially in elderly patients at intermediate or high surgical risk. The Transcatheter Mitral Valve Repair (TMVr) segment is expected to witness the highest CAGR during the forecast period, driven by rising awareness and approvals for mitral valve therapies.

Market by End-use Insights:

Hospitals and Cardiac Centers held the dominant share in 2023, owing to the presence of specialized infrastructure and skilled cardiologists capable of performing complex transcatheter interventions. Increasing patient footfall, combined with government and private investments in cardiovascular centers of excellence, is expected to reinforce the segment’s dominance.

Market by Regional Insights:

North America emerged as the leading region in 2023, supported by a high prevalence of heart diseases, favorable reimbursement policies, and rapid adoption of innovative cardiac procedures. Asia-Pacific is projected to grow at the highest CAGR through 2031, fueled by growing healthcare expenditure, large patient populations, and the entry of global players expanding access to transcatheter technologies.

Competitive Scenario:

Key players in the market include Edwards Lifesciences Corporation, Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, JenaValve Technology, Inc., and LivaNova PLC. These companies are actively investing in research and development, expanding product portfolios, and securing regulatory approvals to strengthen their global market position.

Key Market Developments:

2023: Edwards Lifesciences received FDA approval for its next-gen TAVR system optimized for smaller delivery profiles.

2024: Abbott launched a new iteration of its MitraClip system in Europe aimed at enhancing procedural accuracy.

2025: Boston Scientific acquired a start-up specializing in transcatheter mitral valve replacement technologies to expand its structural heart portfolio.

Scope of Work – Global Transcatheter Heart Valve Replacement and Repair Market

Report Metric Details

Market Size (2023) USD 6.3 billion

Projected Market Size (2031) USD 14.9 billion

CAGR (2023–2031) 11.4%

Key Segments by System Type TAVR, TMVr, TMVR

Key Segments by End-use Hospitals, Cardiac Centers

Leading Region North America

Key Players Edwards Lifesciences, Medtronic, Abbott, Boston Scientific

FAQs

1) What is the current market size of the Global Transcatheter Heart Valve Replacement and Repair Market?

The market size in 2023 is valued at USD 6.3 billion.

2) What is the major growth driver of the Global Transcatheter Heart Valve Replacement and Repair Market?

The major driver is the increasing prevalence of cardiovascular diseases and the growing adoption of minimally invasive procedures.

3) Which is the largest region during the forecast period in the Global Transcatheter Heart Valve Replacement and Repair Market?

North America is the largest region due to high adoption rates and strong healthcare infrastructure.

4) Which segment accounted for the largest market share in Global Transcatheter Heart Valve Replacement and Repair Market?

The TAVR segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Transcatheter Heart Valve Replacement and Repair Market?

Key players include Edwards Lifesciences, Medtronic, Boston Scientific, Abbott Laboratories, and LivaNova.